PM360 2019 Innovative Service AMP: Access for More Patients from CoverMyMeds and RxCrossroads by McKesson

AMP: Access for More Patients™

CoverMyMeds and RxCrossroads by McKesson

Claire Crye, Senior Manager, Public Relations

Patient access requirements for specialty medications are more numerous, time-consuming, and complicated than traditional pharmaceuticals, with patients often struggling to coordinate therapy on their own. To help patients get the medications they need, CoverMyMeds and RxCrossroads by McKesson created an electronic platform for support services—AMP: Access for More Patients.

This customizable platform allows for patient intake to begin at the point-of-prescribing and uses technology to connect all healthcare stakeholders, so they have visibility into patient enrollment and access requirements through a centralized online portal. Designed to be a new starting point for specialty medication access, key features include:

  • Clear Path to Viral Adoption: AMP connects to CoverMyMeds’ web portal utilized by more than 700,000 providers. For some therapeutic areas, over 90% of prospective national provider identifiers (NPIs) have accessed the portal in the last 90 days.
  • Electronic Processes: Patient enrollment and consent, benefits investigation and verification (BI/BV), financial assistance, prior authorization (PA), and scheduling lab tests can be requested or completed electronically to help decrease time-to-therapy for patients.
  • High-Touch Patient Support: When a patient case deviates from the standardized AMP workflow, expert case managers are on standby to fulfill any outstanding tasks for starting therapy.
  • Ongoing Adherence Support: Comprehensive support is available to help patients remain on therapy, from tech-enabled tools to behavioral coaching and clinical support programs that enable better patient outcomes.

During a two-month pilot study for a neurology product, AMP had a positive impact on helping patients start their prescribed specialty therapy with a 27% reduction in time-to-therapy relative to industry standard. Additionally, adoption of AMP by prospective providers reached 89%.


You May Also Like